Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pharming Group N.V (PHAR) Receivables - Other: 2019-2024

  • Pharming Group N.V's Receivables - Other fell 25.59% to $1.6 million in Q4 2024 from the same period last year, while for Dec 2024 it was $1.6 million, marking a year-over-year decrease of 25.59%. This contributed to the annual value of $1.6 million for FY2024, which is 25.59% down from last year.
  • According to the latest figures from Q4 2024, Pharming Group N.V's Receivables - Other is $1.6 million, which was down 25.59% from $2.1 million recorded in Q4 2023.
  • In the past 5 years, Pharming Group N.V's Receivables - Other ranged from a high of $2.4 million in Q4 2021 and a low of $1.1 million during Q4 2022.
  • For the 3-year period, Pharming Group N.V's Receivables - Other averaged around $1.6 million, with its median value being $1.6 million (2024).
  • Its Receivables - Other has fluctuated over the past 5 years, first soared by 169.74% in 2020, then plummeted by 52.73% in 2022.
  • Pharming Group N.V's Receivables - Other (Quarterly) stood at $2.3 million in 2020, then increased by 2.52% to $2.4 million in 2021, then tumbled by 52.73% to $1.1 million in 2022, then surged by 92.03% to $2.1 million in 2023, then fell by 25.59% to $1.6 million in 2024.
  • Its Receivables - Other was $1.6 million in Q4 2024, compared to $2.1 million in Q4 2023 and $1.1 million in Q4 2022.